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Recent evidence suggests that adult bonemarrow stem cells reduce tissue damage and promote repair following
CNS ischemic injury. Since granulocyte-colony stimulating factor (G-CSF) mobilizes hematopoietic stem cells to
the circulating compartment, here we tested whether administration of this drug modifies the outcome of a
permanent occlusion of the middle cerebral artery in adult mice. To elucidate the behavior and fate of blood-
borne cells in the ischemic brain, we produced chimeric animals, in which hematopoietic derivatives are
genetically tagged. G-CSF administration enhances the proliferation ofmicroglia in the uninjured CNS but has no
effect on the amount of hematopoietic cells that infiltrate the ischemic tissue and on the size of the lesion. The
blood-borne elements acquire different mesodermal identities but fail to adopt neural phenotypes, even though
they occasionally fuse with Purkinje neurons. These results indicate that G-CSF treatment does not exert a
significant beneficial effect on the ischemic injury.
© 2010 Elsevier Inc. All rights reserved.
Introduction
Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic
growth factor that stimulates proliferation and specification of neutrophil
precursors (Morrison et al., 1997; Wright et al., 2001) and induces their
large-scalemobilization frombonemarrow (BM) to the peripheral blood
(Levesque et al., 2003; Zou et al., 2004; Katayama et al., 2006). Because of
these properties, G-CSF has been widely used in clinical practice to treat
neutropenia induced by chemotherapy, or in the case of BM transplan-
tation (Welte et al., 1996). Recent studies highlighted the efficacy of G-
CSF in animalmodels of cerebral ischemia, reporting significant reduction
of infarct size and improved functional recovery (Minnerup et al., 2008;
Sevimli et al., 2009; Zhang et al., 2009). The beneficial effects of G-CSF
have been attributed to different concurrentmechanisms, including anti-
apoptotic activity (Schäbitz et al., 2003; Schneider et al., 2005),
immunomodulation (von Aulock et al., 2004), stimulation of neurogen-
esis (Schneider et al., 2005; Kawada et al., 2006; Diederich et al., 2009),
and angiogenesis (Lee et al., 2005). These phenomena have been related
to direct effects of G-CSF on neural cells or to enhanced colonization of
ischemic regions by hematopoietic stem cells (HSCs) (Schäbitz and
Schneider, 2007). The latter cells may produce and release molecules
endowed with neuroprotective or neurotrophic activity (Schäbitz and
Schneider, 2007; Hokari et al., 2009) but could also contribute directly to
nervous tissue repair by adopting local phenotypes (Brazelton et al.,
2000; Mezey et al., 2000) or fusing with damaged neurons (Magrassi et
al., 2007).
The beneficial effects of G-CSF have been consistently observed
following transient cerebral ischemia. Nevertheless, a dose-dependent
expansion of cortical atrophy, associated with severe functional defects,
has been reported following G-CSF administration in a model of
permanent ligation of the middle cerebral artery (MCA) (Taguchi et al.,
2007). These negative outcomes have been attributed to an exaggerated
inflammatory response, consequent to the enhanced G-CSF-induced
infiltration of the infarct region by hematopoietic cells.
In spite of such contrasting reports, and considering their
relevance for a potential use of G-CSF in the clinical treatment of
stroke, little is known about the behavior and fate of blood-borne cells
that colonize the ischemic brain following G-CSF stimulation and the
consequent effects on ischemic injury. To address these issues, here
we evaluated the effect of G-CSF application following permanent
occlusion of the medial cerebral artery (MCAo). In this context, to
relate the effects of G-CSF administration to the mobilization of
hematopoietic elements and to the extension of ischemic brain
damage, we prepared chimeric mice in which blood cells had been
tagged by enhanced Green Fluorescent Protein (eGFP) expression.
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Analysis of these animals was aimed at monitoring the G-CSF-induced
infiltration of the ischemic brain and at identifying the phenotypes
acquired by the blood-borne elements. Our results show a moderate
but consistent activity of G-CSF on the uninjured brain but fail to
disclose significant effects on the extent of the injury, on the amount
of blood cells that colonize the ischemic region, and on their
phenotypic differentiation.
Materials and methods
Animals and surgical procedures
Adult CD1 or C57BL/6 mice (body weight 20–30 g, age 3–6 months;
Harlan, San Pietro al Natisone, Italy) were used for the study. All
experimental procedures on living animals were performed according
to the European Communities Council Directive of 1986 (86/609/EEC),
the National Institutes of Health guidelines, and the Italian law for care
and use of experimental animals (DL116/92) andwere approved by the
ItalianMinistry ofHealth and the Bioethical Committee of theUniversity
of Turin. All efforts weremade tominimize the number of animals used
and their suffering. All surgical procedures and perfusions were carried
out under deep general anesthesia obtained bymeans of intraperitoneal
administration of ketamine (100 mg/kg; Ketavet; Bayer, Leverkusen,
Germany) supplemented by xylazine (5 mg/kg; Rompun; Bayer).
Generation of chimeric mice
Animals. The recipients of BM transplantation were C57BL/6 chimeric
mice (H-2b/CD45.2; Harlan, San Pietro al Natisone, Italy). Donor BM
cells were obtained from 5- to 10-week-old male transgenic mice
derived by outcrossing the original mice that ubiquitously express the
enhanced Green Fluorescent Protein (eGFP) under control of the β-
actin promoter (Okabe et al., 1997).
Conditioning and graft. Mice used as recipients of BM transplants were
conditioned by irradiation with a total dose of 900 cGy from a 60Co
source 24 h before transplantation. Donor mice were killed by cervical
dislocation, their femur and tibias were removed, and marrow was
flushed out of the bones with serum-free, glucose-supplemented Earle
medium (Invitrogen, San Giuliano Milanese, Italy), under sterile
conditions. The suspensionof BM-derived cells for graftingwasobtained
by mechanical dissociation of the marrow fragments. After washing
three times and centrifugation, donor cells were resuspended in Earle
medium to a final concentration of 106 cells in 300 μl. In all recipient
animals, the unfractionated marrow cell suspension was grafted by tail
vein injection.Donor engraftmentwasdetermined byflowcytometry of
peripheral blood. Cytometric analysis was performed on days 20 and 40
after bonemarrow grafting. Chimeric micewere subjected to theMCAo
surgery and to the consequent G-CSF/vehicle/BrdU protocol at about
4 months after the transplantation.
Induction of ischemic lesion
Focal cerebral ischemia was induced according to the model of
Renolleau et al. (1998). This model of permanent MCAo was chosen
because it yields consistent and repetitive results through animals, thus
facilitating the quantitative assessment of cell proliferation and fate,
whichwas the primary goal of ourwork. In addition, a similarmodel has
been previously applied to investigate the effect of other neuroprotec-
tants (de Bilbao et al., 2009; Wang et al., 2010). Briefly, mice were
anesthetized (see above) and the left MCAo was obtained by electro-
coagulating theMCA close to its origin at the junction with the olfactory
branch. A clipwas then placed to occlude the left common carotid artery
(CCA) and was removed after 90 min. Rectal temperature was
maintained at 36.5–37.5 °C throughout the procedure. Sham-operated
mice received the same surgical procedures except that theMCAwasnot
electrocoagulated and the CCA was not occluded. This procedure was
applied because CCA ligation significantly reduces the high variability of
infarct size after MCAo, due to anastomoses that protect the MCA
territory from ischemia.
Drug administration
Human recombinant G-CSF (L03AA02 Filgrastim, Amgen, MI, Italy)
was dissolved in a 5% glucose solution and intraperitoneally injected
(50 μg/kg/day for4 days, starting from3 to6 hafter surgery) to ischemic
or uninjured mice, whereas control animals received vehicle only. This
daily dose of GCS-F is similar to that administered in most studies on
experimental stroke,whereas the cumulative dose is among the highest
used in such reports (Minnerup et al., 2008; Schäbitz and Schneider,
2007; England et al., 2009). The mice also received intraperitoneal
injections of bromodeoxyuridine (BrdU, 50 mg/kg in saline, Sigma, St
Louis, MO) twice a day during the same 4 days of cytokine/vehicle
treatment, according to the same time schedule described above.
The animals were divided into several experimental groups:
unlesioned mice with G-CSF (n=4) or vehicle (n=4), sham-operated
mice with G-CSF (n=4) or vehicle (n=4), MCAo mice with G-CSF
(n=4) or vehicle (n=4). These animals were killed 1 week after the
beginning of the treatment. In contrast, the chimeric mice, which were
specifically destined to the analysis of the fate of hematopoietic cells
infiltrating the injured brain,were all subjected toMCAoand subdivided
in two groups, receiving either G-CSF (n=3) or vehicle (n=3). These
animals were killed 3 weeks after the beginning of the treatment to
identify the mature phenotype acquired by hematopoietic cells.
Histological procedures
At the end of the survival time, under deep general anesthesia (see
above), the animals were transcardially perfused with 500 ml of 4%
paraformaldehyde and 0.8% picric acid solution (Fluka, Buchs,
Switzerland) in 0.12 M phosphate buffer, pH 7.2–7.4. The brains were
immediately dissected, stored overnight in the same fixative at 4 °C, and
finally transferred to 30% sucrose in 0.12 M phosphate buffer, until they
sank. The brainswere cutwith a cryostat in series of 30-μm-thick coronal
slices collected in PBS. The sliceswere immunohistochemically processed
to detect the expression of different cell-specific antigens: Iba1 (1:1000,
rabbit polyclonal, Wako), S100 (1:2000, rabbit polyclonal, DakoCytoma-
tion, Glostrup, DK), Olig2 (1:500, rabbit polyclonal, Chemicon), NeuN
(1:500, mouse monoclonal, Chemicon), CD133 (alias Prominin1; 1:500,
mouse monoclonal, eBioscience, San Diego, CA, USA), Flk (1:50, rat
monoclonal, BD Biosciences, San Jose, CA, USA), factor VIII (von
Willebrandt factor; 1:200, rabbit polyclonal; DakoCytomation, Glostrup,
DK). In case of chimeric mouse tissue, we used anti-GFP antibodies
(1:700, rabbit polyclonal ormousemonoclonal; Invitrogen, Carlsbad, CA)
to enhance the intrinsic fluorescence of BM-derived cells. In addition, the
proliferation studies were performed, thanks to the visualization of BrdU
incorporation by means of anti-BrdU antibody (1:500, rat monoclonal;
Abcam, Cambridge, UK). For BrdU immunohistochemistry, the slices
were pre-incubated in HCl 2 N for 20 min at 37 °C, then washed in PBS
and in borate buffer (0.5 M, pH 8.5) for 10 min at room temperature.
Incubation with primary antibodies was made overnight at room
temperature in PBS with 1.5% normal serum and 0.25% TritonX-100. For
BrdU and eGFP labelling, in some cases, immunohistochemical staining
was performed according to the avidin–biotin–peroxidase method
(Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA, USA)
and revealed using 3,3′-diaminobenzidine (0.03% in Tris–HCl) as a
chromogen. The other series were processed for double immunofluo-
rescence. These sectionswere then exposed for 1 h at room temperature
to secondary biotinylated antibodies followed by a solution of
streptavidin Texas Red conjugate (1:200; Invitrogen) or fluoresceinated
second antibody (1:200; Vector Laboratories). The stained sectionswere
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mounted on microscope slides with Tris–glycerol supplemented with
10% Mowiol (Calbiochem, La Jolla, CA) to reduce fading of fluorescence.
Data analysis
The histological preparations were examined by means of a Zeiss
(Oberkochen, Germany) Axiophot light microscope, equipped with a
Nikon (Melville, NY) DS-5M digital camera. The material was also
examinedwith anOlympus Optical (Hamburg, Germany) Fluoview300
confocal microscope. Digital images were processed with Adobe
Photoshop CS2 (Adobe Systems, San Jose, CA), to adjust contrast and
assemble the final plates. Quantitative and morphometric evaluations
were made using the softwares Image J (Research Service Branch, NIH,
Bethesda, MD) and Neurolucida (MicroBrightField, Colchester, VT), the
latter using a computer interfaced with an E-800 Nikon microscope
equipped with a color CCD camera.
Evaluation of lesion extension
To evaluate the extent of the ischemic injury, we examined series of
30-μm-thick Nissl stained frontal sections, in which we distinguished
uninjured tissue, penumbra, and necrotic core of the lesion. The
boundary between intact tissue and penumbra was identifiable for the
decrease of Cresyl Violet staining and the presence of apoptotic cells.
Necrotic tissuewas readily recognizable asdisrupted tissue at the core of
the injury. By means of Neurolucida, in each section of the series, we
outlined the ischemic hemisphere and the affected tissue (i.e., penumbra
plus core regions). From these data, theNeurolucida software calculated
the respective volumes according to Cavalieri's geometry. Each of the
reconstructionsdisplayed in Fig. 6A–Bencompasses the entire extension
of the ischemic injury (total thickness of about 5 mm, i.e., 25 sections).
Quantitative analyses of cell proliferation and fate
BrdU incorporation. In order to quantify the cellular proliferation in
uninjured, ischemic, and sham-operated mice, we mapped BrdU-
positive cells by Neurolucida and calculated the number of labeled
nuclei per mm2. The analysis was carried out separately in several CNS
subdivisions (e.g., neocortex, basal ganglia, hippocampus) or regions
of interest (e.g., penumbra of the ischemic region), at two different
levels along the rostro-caudal axis. On the whole, several thousand
cells were sampled in each animal of the different experimental sets.
To assess whether G-CSF stimulates neurogenesis in the hippocam-
pus of intactmice,we calculated thenumber of BrdU-positive cells along
the length of the subgranular zone. For each animal, 200–250 labeled
cells were mapped by means of Neurolucida in the hippocampi of both
sides at four different levels along the rostro-caudal axis.
Phenotypic distribution of proliferating cells in intact mice. The identity
of proliferating cells was assessed on double-immunostained material
for BrdU and cell type-specific antigens (Iba1 for microglial cells, S100
for astrocytes and Olig2 for oligodendrocytes, NeuN for neurons). For
each animal, several hundred cells were sampled and mapped in the
hippocampi of both sides at different rostro-caudal levels and the
number of double-labeled cells was expressed as percentage of total
number of BrdU-positive nuclei.
BM-derived cells in chimeric mice. The density of eGFP-positive cells
(number of eGFP-positive cells/mm2) in chimericmicewas quantified as
described above for BrdU incorporation. Briefly, by means of Neurolu-
cida, we reconstructed the maps representing the distribution of blood-
borne cells in several brain areas (neocortex, basal ganglia, hippocam-
pus, penumbra of the lesion) at two different rostro-caudal levels.
To assess whether G-CSF increases the penetration of BM-derived
cells in the intact nervous tissue, we counted the number of eGFP-
positive cells/mm2 in the cerebellum, by mapping at different rostro-
caudal levels and sampling several hundred green cells per animal. The
same material was used to monitor fusion events, by counting the
number of eGFP-labeled Purkinje cells throughout the whole cerebellar
cortex.
Phenotypic characterization in chimeric mice. Phenotype identification
and relative frequencies of eGFP-positive cells were done by
examining sections labeled for different type-specificmarkers. Several
hundred cells were sampled for each animal, and the frequency of the
different types was expressed as the percentage over the whole
population of green cells contained within the sampled tissue.
Statistical analysis
The data are expressed as means±the standard deviations (SD).
Statistical analysis was performed by comparing two groups with the
unpaired Student's t-test. Differences were considered significantwhen
Pb0.05.
Results
G-CSF administration stimulates cell proliferation in the uninjured CNS
The main goal of our work was to assess the effects of G-CSF
administration on the fate of BM-derived cells after ischemia and, hence,
on the evolution of injury itself. Since G-CSF can cross the blood-brain
barrier (Zhaoet al., 2007a),wefirst examined intact animals todetermine
the direct effects of the substance on the CNS, and to set basal conditions
to be comparedwith ischemic injury. Uninjuredmice received injections
of G-CSF or vehicle plus BrdU for 4 days and were killed 7 days
after the beginning of the procedure. Compared to vehicle-injected
animals, G-CSF-treatedmice showeda clear-cut increase in the frequency
of cells that incorporated BrdU in all the brain regions considered,
including cerebral cortex, basal ganglia, and hippocampal formation
(Fig. 1A–F). Quantitative evaluation, performed by mapping BrdU-
retaining nuclei at two different levels along the rostro-caudal axis
(Fig. 1G), revealed no differences between the hemispheres in both
groups (Fig. 1H; G-CSF-treated animals, Student's t-test, P=0.703;
vehicle-treated animals, P=0.806), but showed a significant increase
in the density of BrdU-positive cells after G-CSF administration (Fig. 1H;
left hemisphere, Student's t-test, P=0.037, right hemisphere P=0.047).
The same increase was consistently observed when different
CNS subdivisions were evaluated separately (Fig. 1I, cerebral cortex,
Student's t-test, P=0.045; basal ganglia, P=0.043; hippocampus,
P=0.012).
The increase in BrdU incorporation in the hippocampus suggested
that G-CSF administration could promote neurogenesis. However,
Fig. 1. G-CSF treatment stimulates proliferation of microglial cells in the uninjured CNS. A–F. Distribution of BrdU-positive cells in the cerebral cortex (A, D), hippocampus (B, E), and
basal ganglia (C, F) of uninjured mice. Comparison of vehicle- (A–C) and G-CSF-treated animals (D–F) reveals a consistent increase in the density of proliferating cells after drug
administration. G. Examples of Neurolucida maps showing the distribution of BrdU-positive cells at two rostro-caudal levels. H, I. The graphs illustrate the density of BrdU-positive
cells in control mice after vehicle and G-CSF administration. Analysis of entire hemispheres (H) or of individual brain regions (I) reveals a consistent effect of G-CSF. J–M. Double
immunolabeling for BrdU (green) and NeuN (red) in the dentate gyrus does not reveal colocalization of the markers, as highlighted by the higher magnification insets (K, M), in
which the position of BrdU-positive nuclei is indicated by arrows. N–S. Characterization of proliferating cells in uninjured mice treated with vehicle (N–R) or with G-CSF (O–S). The
micrographs show double-labeled cells (pointed by arrowheads) for BrdU (red) and Iba1 (green, N, O), S100 (green, P, Q), and Olig2 (green, R, S). T–V. Frequency of BrdU-labeled
cells on the population of cells stained for Iba1, S100 or Olig2. CX, cerebral cortex; DG, dentate gyrus; Hippo, hippocampus; BG, basal ganglia; Ctrl, control; he., hemisphere. Asterisks
represent statistically significant differences (see text for levels of significance). Scale bars: A, C, D, F, 400 μm; B, E, N–S, 20 μm; J, L, 40 μm; K, M, 10 μm.
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evaluation of the number of BrdU-positive nuclei along the extension
of the subgranular zone (SGZ) did not reveal significant differences
between G-CSF and vehicle-treated animals (BrdU-positive cells/mm
in G-CSF animals=11.90±2.91; in vehicle animals=12.12±3.92;
Student's t-test, P=0.895). Moreover, we failed to detect cells
double-labeled for BrdU and NeuN in the SGZ or dentate gyrus of
both experimental groups (Fig. 1J–M).
To characterize the cell types that proliferate following G-CSF
treatment, we counted the number of cells double-labeled for BrdU
and different lineage-distinctive markers in the hippocampus, where
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the highest density of labeled nuclei was encountered. In the G-CSF-
treated animals, there was a significant increase of cells double-labeled
for BrdU and the microglial marker Iba1 (Imai et al., 1996; Fig. 1N,
O, T; Student's t-test, P=0.007). On the contrary, no differences between
G-CSF and vehicle-treated groups were found for S100-positive astro-
cytes (Fig. 1P, Q, U; Student's t-test, P=0.406) and Olig-2-positive
oligodendrocytes (Fig. 1R, S, V; Student's t-test, P=0.842). Therefore, the
increase in thenumber of BrdU-positive cells in the intact CNS afterG-CSF
treatment appears to be exclusively sustained by microglia.
Effect of G-CSF administration on cell proliferation in the ischemic brain
To assess whether G-CSF influences cell proliferation in the
injured nervous tissue, we applied the same protocol of BrdU/G-CSF
or BrdU/vehicle administration starting from the day when MCAo
was performed. In the brains of the sham-operated mice, there were
no signs of tissue injury (Fig. 2I), and the pattern of incorporation of
BrdU was similar to that observed in the intact mice (Fig. 2K, M).
Following ischemia, the density of BrdU-retaining cells was strongly
increased in both hemispheres (Fig. 2A–H, J), although labeled
nuclei on the injured side greatly outnumbered those on the
contralateral side (Fig. 2L; G-CSF-treated animals, Student's t-test,
P=0.009; vehicle-treated animals, P=0.005). The values calculated
from ischemic brains were considerably higher than those obtained
from sham-operated mice (Fig. 2K–O; Student's t-test, ischemic
hemisphere vs. sham hemisphere Pb0.005 for both G-CSF and
vehicle-treated mice). On the other hand, no significant differences
were found between G-CSF and vehicle-treated animals in either
hemisphere (Fig. 2L; injured side, Student's t-test, P=0.878;
contralateral side, P=0.904). The same result was obtained by
analyses restricted to the ischemic area or to the different CNS
subdivisions (Fig. 2N, O), except for a higher number of BrdU-
labeled cells in the uninjured hippocampus, which nonetheless
failed to reach statistical significance (Fig. 2O; ipsilateral hemi-
sphere: lesion, Student's t-test, P=0.477; cortex, P=0.741; basal
ganglia, P=0.846; hippocampus, P=0.902; contralateral hemi-
sphere: cortex, P=0.548; basal ganglia, P=0.845; hippocampus,
P=0.061). Phenotypic characterization of BrdU-labeled cells
revealed S100-positive astrocytes (Fig. 3A, B), Iba1-positive micro-
glia (Fig. 3C, D), and Olig2-positive oligondrocyte precursors (Fig.
3E, F). On the contrary, we failed to observe cells double-labeled for
BrdU and the neuronal marker NeuN (Fig. 3G, H).
The infiltration of BM-derived cells in the ischemic injury site is not
influenced by G-CSF administration
To assess whether G-CSF promotes the infiltration of blood-borne
cells in the ischemic tissue, we induced permanent MCAo in chimeric
mice, in which hematopoietic elements had been replaced by eGFP-
expressing cells. In order to identify the mature phenotypes acquired
by the immature blood cells recruited into the lesioned parenchyma,
these animals were killed 3 weeks after surgery (followed by G-CSF/
BrdU or vehicle/BrdU administration protocol).
We first asked whether G-CSF facilitates the ability of BM-derived
cells to colonize the intact CNS tissue. Since all chimeric animals
underwent MCAo, we evaluated the frequency of eGFP-positive cells in
the cerebellum,which is not directly affectedby the ischemic insult. This
analysis did not reveal any difference in the number of BrdU-positive
cells/mm2 between drug or vehicle-treated groups (G-CSF=37.17±
7.19; vehicle=39.34±8.47; t-test P value=0.752).
Analysis of the histological sections of the hemispheres revealed
similar distribution patterns of eGFP-positive cells after G-CSF or
vehicle administration (Fig. 4A–I). BM-derived cells were preferen-
tially located inside or surrounding the ischemic lesion, although they
were present throughout the examined tissue. Green cells were more
frequent in the injured than in the intact hemisphere (Fig. 4J), but
there were no clear differences between G-CSF and vehicle-treated
mice, although the number of green cells/mm2 in the hemisphere
contralateral to MCAo was slightly higher in the latter group (Fig. 4J;
Student's t-test, P=0.037).
Fig. 3. Characterization of proliferating cells in the ischemic brain. The pictures represent double-labeled cells for BrdU (green) and type-specific antigens (red). Proliferating S100-
positive astrocytes (A, B, arrowheads), Iba1-positive microglial cells (C, D, arrowheads), and Olig2-expressing oligodendrocytes (E, F, arrowheads) can be detected in the vicinity of
the lesion. On the contrary, no NeuN-positive nuclei are also labeled with BrdU (arrowheads), both in the hippocampus (G) and in the cerebral cortex (H) ipsilateral to the injury.
Scale bars: A, B, H 10 μm; E, C, 40 μm; F, D, 20 μm; G, 50 μm.
Fig. 2. G-CSF administration does not affect proliferation following ischemic damage. A–H. Distribution of BrdU-positive cells in the whole ischemic hemisphere (A, E), cerebral
cortex (B, F), hippocampus (C, G), and ischemic area (D, H) of G-CSF- (E–H) and vehicle-treated mice (A–D). I. Nissl-stained sections show the absence of CNS injury in sham-
operated mice. J. Examples of Neurolucida maps showing the distribution of BrdU-positive cells at two rostro-caudal levels. K–L. The graphs illustrate the density of BrdU-positive
cells in the entire hemispheres of G-CSF and vehicle-injected mice that underwent sham surgery (K) or MCAo (L). In shammice, G-CSF induced a significant increase of proliferating
cells in both hemispheres (Student's t-test, Pb0.01). In contrast, following MCAo, there was a huge increase of BrdU-labeled nuclei, particularly in the injured hemisphere. However,
no difference was observed between G-CSF and vehicle-treated animals. M–O. Analysis of individual CNS regions yielded similar results: the moderate increase of BrdU labeling
consistently observed following G-CSF administration to sham animals (M; Student's t-test, Pb0.01) wasmasked by the huge effect of ischemic injury (N, O; please note the different
scales of the graphs showing data from sham and MCAo mice). MCAo, middle cerebral artery occlusion; CX, cerebral cortex; Hippo, hippocampus; Les, lesion; Ipsilat. He., ipsilateral
hemisphere; Contralat. He., contralateral hemisphere; BG, basal ganglia. Asterisks represent statistically significant differences (see text for levels of significance). Scale bars: A, E,
2000 μm; B–D, F–H, 400 μm; I, 4000 μm.
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The majority of BM-derived cells that infiltrate the ischemic tissue
differentiate into activated microglia and macrophage-like cells
To identify the mature phenotype acquired by the BM-derived
cells in the tissue surrounding the ischemic core, we analyzed their
morphology and the expression of cell type-specific markers. eGFP-
positive cells that infiltrate the ischemic penumbra showed features
suggestive of migratory behavior (Fig. 4K), whereas those located in
the irreversible ischemic core were tightly clustered and exhibited the
round-shaped and vacuolar morphology of activated macrophages
(Fig. 4L).
The phenotypic analysis of eGFP-positive cells present in the
injured tissue revealed a rather wide repertoire of cell types but
failed to disclose any difference between G-CSF and vehicle-treated
groups. Some green cells were co-labeled with CD-133, which is
distinctive for immature hematopoietic cells (Wognum et al., 2003;
Corbeil et al., 2001) (Fig. 4V–Y; G-CSF: 7.41±1.18% of eGFP-positive
cells; vehicle: 6.37±0.62%; Student's t-test, P=0.268). A conspicu-
ous amount of small eGFP-expressing cells with several tiny
processes were labeled by the microglial marker Iba1 (Fig. 4R–T;
G-CSF: 41.28±9.37%, vehicle: 49.55±0.77%; Student's t-test,
P=0.265), whereas a smaller fraction showed the morphological
features and neurochemical profiles of endothelial cells (Fig. 4M–O;
G-CSF: 4.92±0.84%; vehicle: 3.62±1.41%; Student's t-test,
P=0.257). Concerning neural phenotypes, we never observed any
green-fluorescent cell displaying structural features and type-
distinctive markers of astrocytes (Fig. 4P), oligodendrocytes
(Fig. 4Q), or neurons (Fig. 4U). Within the whole brain, the only
green cells with neuronal morphology were some Purkinje cells
scattered through the cerebellar cortex, whose eGFP expression
results from the fusion with hematopoietic cells (Alvarez-Dolado et
al., 2003; Magrassi et al., 2007). Interestingly, such neurons were
more numerous in G-CSF-treated animals than in the vehicle-treated
group (Fig. 5A, B; Student's t-test, P=0.048).
G-CSF does not reduce the extent of the ischemic injury
To ask whether G-CSF administration modifies the extension of the
ischemic injury, we produced serial section reconstructions of the
affectedhemispheres tomeasure the volumeof the lesion1 and3 weeks
after MCAo (Fig. 6A, B). Comparison of the lesion volumes, expressed as
the percentage of the respective hemisphere, did not reveal any
significant difference at either time points (Fig. 6C, D; Student's t-test,
P=0.907).
Discussion
Starting from recent evidence suggesting that BM-derived stem cells
promote repair and recovery following ischemic brain injury, we asked
whether pharmacological mobilization of these cells can help to
ameliorate the outcome of permanent MCAo, a condition that
reproduces the features of human ischemic stroke (STAIR, 1999; Mohr
et al., 2004). Our results show that, although G-CSF stimulates mitotic
activity of microglia in the intact brain, it has no clear promoting effect
on the proliferation of blood-borne cells and on their ability to infiltrate
Fig. 5. G-CSF increases fusion of BM-derived cells with Purkinje neurons. A. A cerebellar
Purkinje cell expressing eGFP after fusion with a BM-derived cell in a chimeric mouse.
B. Quantification of eGFP-positive Purkinje cells in chimeric mice treated with vehicle or
G-CSF. MCAo, middle cerebral artery occlusion. Asterisks represent statistically
significant differences (see text for levels of significance). Scale bar: 100 μm.
Fig. 6. Effects of G-CSF treatment on the size of the ischemic injury. A–B. Three-
dimensional reconstructions of the ischemic hemispheres in vehicle- (A) and G-CSF-
treated mice (B), obtained by analysis with Neurolucida of Nissl-stained serial sections.
In this graphic illustration, the lesion is represented in green, while the tissue of the
ipsilateral hemisphere is depicted in light blue. Each reconstruction encompasses the
entire extension of the ischemic lesion (total thickness about 5 mm). C–D. Comparison
of injury volumes, represented as percentage of the ipsilateral hemisphere, in vehicle
and G-CSF-treated mice, 1 (C) or 3 weeks (D) after MCAo. MCAo, middle cerebral artery
occlusion.
Fig. 4. Fate of BM-derived cells in the ischemic tissue. A–H. Distribution of eGFP-positive cells in thedorsal half of thehemisphere ipsilateral to the lesion (A, E), hippocampus (B, F), cerebral
cortex (C, G), and inside the damaged tissue (D, H) of chimericmice treatedwith vehicle (A–D) or G-CSF (E–H). I. Examples of Neurolucidamaps showing the distribution of BrdU-positive
cells at two rostro-caudal levels. J. The graph illustrates the density of eGFP-positive cells in the entire hemisphere of both G-CSF and vehicle-injected chimeric mice. K–L. Morphology of
eGFP-positive cells in the ischemic tissue. M–Y. Phenotypic characterization of BM-derived cells (green) by immunolabeling with type-specific markers (red): many of the green cells are
stained for endothelial markers (Flk, M; factor VIII, N; pointed by arrowheads) and display endothelial morphology (O). BM cells do not stain for macroglial (S100, P; Olig2, Q) or neuronal
(NeuN,U) antigens, but they are labeled by themicroglialmarker Iba1 (R–T). Inaddition, numerousgreen cells located near to the ischemic site are stainedbyCD133 antibody (V–Y; pointed
by arrowheads in V). MCAo, middle cerebral artery occlusion; Hippo, hippocampus; CX, cerebral cortex; Les, lesion; Ipsilat. He., ipsilateral hemisphere; Contralat. He., contralateral
hemisphere. Asterisks represent statistically significant differences (see text for levels of significance). Scale bars: A, E, 1000 μm;B–D, F–H, 200 μm;K, 100 μm; L–N, O, R–T,W–Y, 10 μm;P, U,
V, 50 μm; Q, 20 μm.
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the injured tissue. Accordingly, the size of the ischemic damage is not
significantly reduced. Therefore, our observations indicate that, at least
in the present experimental conditions, G-CSF treatment has no major
effect on the outcome of the ischemic injury.
Effects of G-CSF administration in the intact CNS
In intact or sham-operated animals, G-CSF treatment induced a
clear-cut increase in BrdU incorporation that was consistent in all the
examined telencephalic regions. Phenotypic characterization of the
proliferating populations showed that this effect exclusively involved
microglia, whereas neural lineages were unaffected. In addition, in
spite of the increased frequency of BrdU-labeled nuclei in the
hippocampus of G-CSF-treated mice, no difference was found in the
subgranular zone, indicating that the cytokine does not promote
neurogenic processes. These results were somewhat surprising, given
that both G-CSF and the cognate receptor are expressed by adult
intact neurons (Schneider et al., 2005). It is likely that, at the doses
used in our study, the exogenous G-CSF does not add much to the
effect exerted by the endogenously produced substance. Thus,
although our data do not exclude the proposed neurogenic and
anti-apoptotic role played by G-CSF on neurons, they fail to show an
additive effect induced by the pharmacological administration of the
cytokine.
The increase of BrdU incorporation inmicroglia couldbedue either to
direct stimulation of proliferation in resident cells in the CNS
parenchyma or enhanced infiltration by blood-borne elements. Our
analysis of uninjured regions (the cerebellum) in the chimericmice does
not favor the latter explanation, since we did not find more eGFP-
positive cells in the cerebella of G-CSF-treated animals. In this context,
the higher frequency of fusionwith Purkinje cells (Alvarez-Dolado et al.,
2003; Magrassi et al., 2007) is also consistent with a direct stimulating
effect of the drug on microglia. Indeed, fusion events in the cerebellar
cortex are increased following injury and activation of microglia
(Magrassi et al., 2007). Therefore, our observations indicate that
systemically administeredG-CSF influences thebehavior of cells residing
in the CNS but does not increase CNS colonization by circulating cells.
Effects of G-CSF administration on the ischemic CNS
Following ischemia, G-CSF treatment had no effect on cell
proliferation or on the infiltration of eGFP-positive cells in the lesioned
tissue. The densities of BrdU-positive nuclei or of green cells in ischemic
regions were several fold higher than those estimated in intact brains.
MCAo severely disrupts the blood-brain barrier and induces a strong
tissue reaction to the ischemic insult (Fagan et al., 2004). These
phenomena are associated with the release of a wide range of bioactive
molecules, including cytokines such as G-CSF (Schäbitz et al., 2003;
Komine-Kobayashi et al, 2006), and massive infiltration of circulating
cells (leucocytes, Yilmaz and Granger, 2010; mast cells, Strbian et al.,
2009). These incoming blood-borne cells play different roles in the
evolution of brain infarct. For example, mast cells may contribute to
disrupt the blood-brain barrier and favor hemorrhage, whereas their
stabilization leads to reduction of brain oedema and infarct size (Strbian
et al., 2009). On the other hand, activation of immune cells may be
neuroprotective and beneficial to repair phenomena (Stoll et al., 1998).
Recently, it has been shown that accumulation of microglia precedes
that of macrophages, lymphocytes, dendritic cells, and neutrophils
(Gelderblom et al., 2009). Macrophages and microglia have been
reported to gather preferentially in the penumbra, where they
proliferate (Schroeter et al., 1999). Microglia are a double-edged
sword, since they produce toxic molecules and proinflammatory
cytokines, but they also release molecules involved in tissue repair
(Gelderblom et al., 2009). The intensity of these phenomena clearly
overwhelms the activity of the exogenous G-CSF and masks its direct
effects, as also proposed by Komine-Kobayashi et al. (2006).
In line with these observations is the failure of G-CSF to reduce the
infarcted volume. Indeed, previous studies on the effect of G-CSF
treatment in experimental ischemia reported somewhat controversial
results, including reduction of the injury size and improved recovery
(Six et al., 2003; Lee et al., 2005; Schneider et al., 2005; Kawada et al.,
2006; Komine-Kobayashi et al., 2006; Morita et al, 2007; Sehara et al,
2007; Zhao et al, 2007b,c; Toth et al, 2008; Solaroglu et al., 2009; for
review see Minnerup et al., 2008; Bråtane et al., 2009), no significant
effect (Popp et al, 2009), and even increased extension of the lesioned
tissue (Taguchi et al., 2007). Comparisonof thepublisheddata, however,
is hampered by the high variability of experimental conditions,
concerning the procedures used to induce ischemia and the methods
applied to evaluate the time course of the consequent phenomena.
In particular, a recent systematic review of the literature concluded that
G-CSF induces a significant reduction of the injured tissue in case of
transient but not permanent models of ischemic stroke (England et al.,
2009). In addition, in some studies, beneficial effects are only observed
when G-CSF is combined with other injury-induced cytokines (Zhao
et al, 2007c). Taken together, these observations indicate that the
efficacy of G-CSF application depends on several concurrent conditions,
whose definition is crucial in the perspective of a therapeutic use.
To gain further insights about the phenotype and fate of BM-
derived cells in the ischemic injury, we generated chimeric mice in
which these cells are taggedwith eGFP. Three weeks after injury, huge
amounts of green cells had colonized the damaged area and the
surrounding tissues, including wide regions of both hemispheres. The
cells in the ischemic core showed typical features of macrophages,
whereas elsewhere, they mostly acquired the morphology and
neurochemical profiles of microglia or endothelium. Some of the
cells remained undifferentiated, but none of them adopted neural
identities. This phenotypic repertoire was qualitatively and quantita-
tively similar in both experimental groups, showing that G-CSF did
not influence the fate choice and differentiation of BM-derived cells.
On thewhole, our observations indicate thatG-CSF administrationhas
no major beneficial effect on the outcome of CNS ischemia. In particular,
the drug did not overtly affect the quality and the quantity of circulating
BM-derived cells that infiltrate the injured CNS tissue. These cells should
be responsible for stimulating compensatory phenomena and repair
(Schwarting et al., 2008). Hence, the failure of G-CSF to promote their
colonization of the injured tissue explains the lack of positive outcomes.
Nonetheless, the valuable activity of the substance, which iswitnessed by
its clear effect on the intact CNS, should not be disregarded. Indeed, it is
likely that significant results can only be obtained by combining different
molecules with complementary properties and synergistic mechanisms
of action and targets (Liu et al., 2010). In other words, an efficient
treatment to ameliorate the evolution of ischemic CNS injury requires a
cocktail of molecular mediators applied through specifically tailored
spatio-temporal schedules.
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